A multinational research team has discovered that graphene quantum dots (GQDs)—nanoscale carbon particles—can interfere with the aggregation of misfolded proteins associated with neurodegenerative diseases such as Parkinson’s disease and multiple system atrophy (MSA). The findings, published in the journal Science and Technology of Advanced Materials (STAM), point to a new direction for therapeutic exploration in synucleinopathies.
The buildup of a protein called α-synuclein (ASN) into toxic clumps is a hallmark of synucleinopathies, a group of neurodegenerative diseases that includes Parkinson’s and multiple system atrophy. These aggregates are associated with cellular dysfunction and lead to progressive neuronal loss. Because current treatments only manage symptoms rather than stopping the underlying protein clumping, scientists are exploring new strategies, including nanomaterials that can prevent these aggregates from forming or help clear them from the brain.
Led by Professor Małgorzata Kujawska at the Poznań University of Medical Sciences in Poland, the research team tested GQDs in cell-free environments, neuronal cultures, and animal models of MSA. The study found that when GQDs were administered intranasally in mice, the particles significantly reduced the presence of toxic protein aggregates. Furthermore, the treatment appeared to activate autophagy, a biological recycling process that helps cells break down and remove damaged proteins.
“This study points to a promising new direction for strategies against neurodegenerative diseases,” says Professor Kujawska. “While clinical use of GQDs remains a long way off, these findings strengthen the case for further research.”
At concentrations relevant to its biological effects, the GQD showed a favorable safety profile, although some changes in cellular stress and immune responses were observed at higher doses. This is an important consideration, as many nanomaterials face hurdles in medical applications due to concerns over long-term biocompatibility.
While the results are promising, challenges remain, such as preventing quantum dots from clumping in liquid suspensions. “GQDs may serve as a useful research tool,” says Professor Kujawska. “What we learn as we optimize their properties and conduct a comprehensive safety evaluation could help design more effective nanomaterial-based strategies not just for synucleinopathies, but also for other conditions characterized by the buildup of toxic proteins.”
The research was published in the open access journal Science and Technology of Advanced Materials, which publishes outstanding research articles across all aspects of materials science.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Graphene Quantum Dots Show Promise in Targeting Parkinson’s-Related Protein Clumping.